Cytosorbents (NASDAQ:CTSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report released on Friday morning. The firm issued a hold rating on the medical research company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a report on Monday, November 11th.

Cytosorbents Stock Performance

NASDAQ:CTSO opened at $0.92 on Friday. Cytosorbents has a 12 month low of $0.70 and a 12 month high of $1.92. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The firm has a market capitalization of $50.03 million, a PE ratio of -2.54 and a beta of 0.57. The business’s fifty day moving average price is $0.95 and its 200 day moving average price is $1.02.

Institutional Investors Weigh In On Cytosorbents

Hedge funds have recently modified their holdings of the stock. Sargent Investment Group LLC increased its stake in Cytosorbents by 13.4% during the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock worth $2,439,000 after acquiring an additional 192,747 shares during the last quarter. CM Management LLC raised its holdings in Cytosorbents by 3.0% in the second quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after buying an additional 25,000 shares during the period. Geode Capital Management LLC lifted its position in Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after buying an additional 32,415 shares in the last quarter. Finally, Atomi Financial Group Inc. purchased a new position in Cytosorbents in the third quarter valued at about $51,000. 32.87% of the stock is owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.